Phreesia, Inc.
NYSE:PHRMedical - Healthcare Information Services
+$0.08 today
- Market cap
- $760.99M
- Beta
- 0.88
- P/E (TTM)
- 62.6
- EPS (TTM)
- $0.15
Volume 0.86M
Average 1.97M
PHR Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Phreesia, Inc.NYSE: PHR
Financing Cash Flow · Q1 FY2027 · quarter ended Apr 2026
Financing cash flow growth accelerates
Q1 FY2027 financing cash flow of $24.24M (cash outflow) rose 2793.1% year over year, ahead of the +570.9% change in trailing-twelve-month financing cash flow.
Context
- Financing cash flow amounted to 15.2% of revenue in FY2026, up 12.4 pp from a year earlier.
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +2793.1% holds above the trailing-twelve-month pace of +570.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2026
- 72.85M USD
- Year-over-year change
- +734.3%
- 4-year CAGR
- -25.4%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2026 | 2026-01-31 | 72.85M | +734.3% |
| FY2025 | 2025-01-31 | (11.49M) | +32.9% |
| FY2024 | 2024-01-31 | (17.12M) | +17.7% |
| FY2023 | 2023-01-31 | (20.8M) | -108.9% |
| FY2022 | 2022-01-31 | 234.97M | — |
Financing Cash Flow vs competitors
How PHR compares with its peers on the latest reported figures
- PHR's LTM Apr 2026 financing cash flow of $49.45M is the 7th largest of the 11 companies compared; the peer median is $17.42M.
- Its year-over-year change of +570.9% is the 2nd highest of 11, against a peer median of -28.9%.
- Financing cash flow amounts to 10.0% of revenue for PHR, versus a peer median of 18.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $554.87M | -7669.8% | — | 22.1% | |
| LTM Mar 2026 | $456.76M | -579.0% | — | 67.7% | |
| LTM Jan 2026 | $361.98M | +183.3% | — | 432.4% | |
| LTM Mar 2026 | $219.96M | -9.7% | +118.4% | 18.0% | |
| LTM Mar 2026 | $145.87M | -48.2% | +24.9% | 18.5% | |
| LTM Mar 2026 | $135.97M | +9861.1% | +101.4% | 48.0% | |
| LTM Apr 2026 | $49.45M | +570.9% | — | 10.0% | |
| LTM Sep 2026 | $28.87M | -73.5% | -26.1% | 10.9% | |
| LTM Aug 2026 | $19.01M | -81.4% | -5.6% | 2.2% | |
| LTM Mar 2026 | $15.83M | +79.4% | — | 15.9% | |
| LTM Sep 2026 | $4.14M | +45.0% | +11.6% | 1.5% | |
| Peer median (excluding PHR) | $17.42M | -28.9% | +18.3% | 18.2% | |
Competitors are the stored peer set for PHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jan 2022 | FY2023 Jan 2023 | FY2024 Jan 2024 | FY2025 Jan 2025 | FY2026 Jan 2026 |
|---|---|---|---|---|---|
| Net Income | (118.16M) | (176.15M) | (136.89M) | (58.53M) | 2.31M |
| Depreciation & Amortization | 21.3M | 25.3M | 29.49M | 27.89M | 31.45M |
| Deferred Income Tax | 143K | 434K | 228K | 214K | (13.27M) |
| Stock-Based Compensation | 36.14M | 58.78M | 71.7M | 66.98M | 67.45M |
| Change in Working Capital | (18.57M) | (3.86M) | (1.64M) | (6.49M) | (14.09M) |
| Accounts Receivables | (10.22M) | (11.13M) | (11.21M) | (8.81M) | (10.15M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.88M | 4.77M | (1.99M) | (3.23M) | 5.26M |
| Other Working Capital | (11.24M) | 2.5M | 11.56M | 5.55M | (9.2M) |
| Other Non-Cash Items | 4.43M | 5.37M | 4.73M | 2.33M | 4.96M |
| Operating Cash Flow | (74.71M) | (90.12M) | (32.38M) | 32.38M | 78.81M |
| Capital Expenditures | (30.81M) | (26.2M) | (25.1M) | (24.09M) | (11.1M) |
| Acquisitions (Net) | (34.42M) | 0 | (14.57M) | 0 | (153.19M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 15.71M |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (12.39M) | (21.47M) | (19.29M) | (15.38M) | (13.3M) |
| Investing Cash Flow | (65.23M) | (26.2M) | (39.67M) | (24.09M) | (161.88M) |
| Debt Repayment | (4.27M) | (5.95M) | (6.78M) | (7.81M) | 83.18M |
| Common Stock Issued | 245.81M | 4.92M | 0 | 3.93M | 3.83M |
| Common Stock Repurchased | (9M) | (19.38M) | (12.18M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.42M | (397K) | 1.84M | (7.61M) | (14.15M) |
| Financing Cash Flow | 234.97M | (20.8M) | (17.12M) | (11.49M) | 72.85M |
| Effect of Forex Changes | 0 | 0 | 0 | (106K) | (176K) |
| Net Change in Cash | 95.03M | (137.13M) | (89.16M) | (3.3M) | (10.39M) |
| Free Cash Flow | (105.52M) | (116.33M) | (57.48M) | 8.29M | 67.71M |
Phreesia, Inc.
NYSE:PHR
Intrinsic Alpha fair value
Locked
Current Price
$12.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.